[go: up one dir, main page]

US20040005364A1 - Antimicrobial and immunostimulating composition - Google Patents

Antimicrobial and immunostimulating composition Download PDF

Info

Publication number
US20040005364A1
US20040005364A1 US10/460,760 US46076003A US2004005364A1 US 20040005364 A1 US20040005364 A1 US 20040005364A1 US 46076003 A US46076003 A US 46076003A US 2004005364 A1 US2004005364 A1 US 2004005364A1
Authority
US
United States
Prior art keywords
silver
composition
glucan
mesh
wound dressing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/460,760
Other languages
English (en)
Inventor
Barbara Klein
Leo Katzner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BRENNEN MEDICAL LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/460,760 priority Critical patent/US20040005364A1/en
Assigned to BRENNAN MEDICAL, INC. reassignment BRENNAN MEDICAL, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KATZNER, LEO D., KLEIN, BARBARA K.
Publication of US20040005364A1 publication Critical patent/US20040005364A1/en
Assigned to BRENNEN MEDICAL, LLC reassignment BRENNEN MEDICAL, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BRENNEN MEDICAL, INC.
Priority to US11/428,929 priority patent/US20060240083A1/en
Assigned to BRENNEN MEDICAL, INC. reassignment BRENNEN MEDICAL, INC. CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF THE RECEIVING PARTY FROM BRENNAN MEDICAL, INC. TO BRENNEN MEDICAL, INC. PREVIOUSLY RECORDED ON REEL 014413 FRAME 0181. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECT NAME OF THE RECEIVING PARTY IS BRENNEN MEDICAL, INC AS SHOWN ON THE ATTACHED CORRECTED ASSIGNMENT. Assignors: KATZNER, LEO D., KLEIN, BARBARA K.
Priority to US13/156,566 priority patent/US8231894B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
    • A61L2300/104—Silver, e.g. silver sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/23—Carbohydrates
    • A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/426—Immunomodulating agents, i.e. cytokines, interleukins, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention relates generally to an antimicrobial and immunostimulating medical composition which may be adapted for use topically or as part of a mesh matrix which may be further adapted for use as a wound dressing or as a surgical mesh.
  • the present invention provides a medical composition that has the immunostimulating properties common to the topical compositions, wound dressings, and surgical meshes described in the aforementioned patents and patent application, along with antimicrobial properties that aid in preventing or alleviating infection. Consequently, a medical composition according to the present invention comprises an antimicrobially effective and immunostimulating amount of a combination of a ⁇ -glucan component and a silver-containing component.
  • the ⁇ -glucan component is suitably derived from a cereal such as oats, wheat or barley, but may also be derived from yeast, bacteria, and fungus.
  • the medical composition of the present invention may suitably include a cereal-derived ⁇ -D-glucan derived from one of wheat, oats, and barley.
  • An especially beneficial form of ⁇ -D-glucan is characterized as (1-3)(1-4) ⁇ -D-glucan derived from oats, wheat, or barley.
  • the silver component of the medical composition is suitably chosen from a group comprising elemental silver, silver nitrate, silver bromide, silver sulfate, silver fluoride, silver iodide, silver chloride, silver oxides, silver protein, silver lactate, silver citrate, and silver sulfadiazine.
  • a topical composition formulated according to the principles of the present invention may take the form of a an unguent, a cream, a gel, an emollient, an oil or a lotion.
  • the medical composition of the present invention may form a layer of a biocompatible surgical mesh or may be impregnated into a mesh matrix of such a surgical mesh.
  • the medical composition may also form a layer of a wound dressing or may be impregnated into a mesh material of a wound dressing.
  • a wound dressing comprising the medical composition of the present invention may include a mesh material that has a coating that includes a ⁇ -glucan compound and elemental silver or a silver compound.
  • the wound dressing may include a polymeric film of vapor-permeable material bonded to one side of the coated mesh material, as an exterior surface of the wound dressing.
  • Methods for manufacturing the medical compositions described herein are also provided.
  • the invention further provides methods for treating tissue damaged by wound or burn, and methods for treating or repairing tissue at a surgical site.
  • FIG. 1 is a side view of a wound dressing incorporating the medical composition of the present invention.
  • FIG. 2 is a side view of a surgical mesh incorporating the medical composition of the present invention.
  • Each of the components of the medical composition described herein serves a particular function or functions, and is available in purities conducive for use in the particular applications.
  • a component may comprise United States Pharmacia (USP), National Formulary (NF), or other purified grade appropriate for topical use on burns and wounds on the skin, or for internal use when required.
  • the medical compositions of the invention may be prepared from the stated components, and any other additives, using conventional methods.
  • the preferred active ingredients of the medical composition of the present invention are a ⁇ -glucan compound and a silver compound.
  • ⁇ -glucans Compounds classified as ⁇ -glucans comprise a large group of higher molecular weight polymers containing glucopyranosyl units in ⁇ -linked chains.
  • ⁇ -glucans are found in essentially all living cells that are enclosed by cell walls and have considerable structural variation depending on the source.
  • ⁇ -glucans are highly unbranched homopolysaccharides and are isomerically disposed to ⁇ -D-glucan (e.g., starch), which is typically non-functional as a structural support component of the cell.
  • ⁇ -glucans generally comprise a large number of glucopyranosyl units linked primarily by (1-3) and (1-4) linkages.
  • Various types of ⁇ -glucans are described in U.S. Pat. No. 5,980,918 to Klein, which was incorporated by reference above.
  • ⁇ -glucans have a strong immunostimulating property, which makes them ideal for use in medical compositions applied to wounds and surgical sites.
  • the ⁇ -glucans actually stimulate the immune response of the tissues at the wound or surgical site, which has the effect of improving tissue regeneration and speeding recovery.
  • ⁇ -glucan compounds have historically been yeast and bacterial cells.
  • the most readily available types of ⁇ -glucans presently are those derived from yeast, bacteria, fungi and from cereal grains such as wheat, barley, and oats. All of these ⁇ -glucans may be used to formulate the medical composition of the present invention.
  • Cereal-derived ⁇ -D-glucan is significantly different from ⁇ -glucans obtained from other sources, including ⁇ -D-glucans derived from yeast such as Saccharomyces cerevisiae and bacteria such as Cellulomonas flavigena .
  • the cereal-derived (1-3)(1-4) ⁇ -D-glucan is distinctive from microbial-derived glucans, which have all (1-3) linkages or primarily (1-3) linkages with a few (1-6) linkages.
  • the molecular weight of the mixed-linkage cereal-derived ⁇ -glucan suitable for use in this invention is generally much greater than that of microbial-derived glucans.
  • Suitable cereal-derived ⁇ -glucan compounds may span a fairly broad range of molecular weights, i.e., from about 1 kDa to about 1,500 kDa, and preferably from 200 kDa to 700 kDa.
  • cereal derived ⁇ -glucans have been shown to be the most efficacious in stimulating the immune response of the tissues at a wound or surgical site. Therefore, it is preferred to utilize cereal-derived ⁇ -glucans such as those derived from wheat, barley and oats as the ⁇ -glucan component of the medical composition of the present invention.
  • Cereal-derived glucan may be characterized as follows:
  • CDG is a long chain, unbranched polysaccharide which typically makes up about 3-4% of oat and barley grains.
  • the CDG concentration is greater, e.g. 7-10%, in the milled bran fraction of oats.
  • CDG is found in the endosperm and aleurone cell walls of most cereal grains.
  • the microbe-derived glucans occur in the cell wall of the yeast or bacteria.
  • CDG is a mixed-linkage molecule containing about 70 percent (1-4)-linkages and about 30 percent (1-3)-linkages.
  • the (1-3)-linked units mostly occur singly whereas the (1-4)-linked units typically occur in groups of three or four glucopyranosyl units.
  • the resultant structure is a series of short runs of 3 or 4 (1-4)-linked glucopyranosyl units, adjacent runs connected by (1-3) linkages.
  • the frequencies of the groups of three (cellotriosyl) and four (cellotetraosyl) glucopyranosyl units also tend to be characteristic of the source, being affected by cereal variety, tissue age, and stage of maturity.
  • Oat-derived CDG typically has more of the groups of three consecutive (1-4)-linked glucopyranosyl units than does barley-derived CDG.
  • the ratio of trisaccharide to tetrasaccharide groups is about 2:1 for oats and closer to 3:1 for barley.
  • CDG differs from microbe-derived glucans, which have all (1-3)-linkages or mostly (1-3)-linkages with some (1-6)-linkages.
  • CDG is a linear molecule, while yeast-derived glucan forms a helical shape.
  • the degree of polymerization of CDG is in the range of about 1200-1800.
  • yeast-derived ⁇ -D-glucan has a much lower degree of polymerization, i.e. about 60-80.
  • Cellulose the primary constituent of plant cell walls, has all ⁇ (1-4) linkages and a degree of polymerization of about 10,000 to 15,000.
  • CDG forms viscous solutions in warm water.
  • yeast-derived glucan is insoluble in water but dispersible in aqueous systems.
  • CDG occurs within the grain with a fairly broad range of molecular weights, i.e. about 200 kDa to about 700 kDa.
  • the molecular weight is believed to be dependent upon the grain species, grain source, glucan extraction conditions and particular laboratory.
  • Microbe-derived glucan has a much lower molecular weight, in the range of about 10 kDa to about 14 kDa.
  • Cellulose has a molecular weight of about 700 kDa.
  • CDG as a food component has been studied extensively by various researchers; studies have included the use of CDG in regulation of glucose metabolism, hypoglycemic response, reduction in serum cholesterol, and the like.
  • CDG is much more like cellulose than are the microbial-derived glucans.
  • the preferred active agent is ⁇ -D-glucan derived from oats, although the glucans from barley, wheat and/or other cereal grains may be used for the topical composition, provided the ⁇ -D-glucan can be extracted economically.
  • the second active ingredient of the medical composition of the present invention is a silver-containing component providing antimicrobial properties.
  • the silver-containing component may be a silver compound or other source of silver that is capable of releasing elemental silver or silver ion in situ.
  • Silver-containing components suitable for use with the medical composition of the present invention act to kill or inhibit the growth of bacteria or other infectious agents that may be present at a wound or surgical site.
  • Silver-containing components suitable for use with the medical composition of the present invention comprise elemental silver, or silver compounds including inorganic silver salts such as silver nitrate, silver bromide, silver sulfate, silver fluoride, silver iodide, silver chloride and silver oxides, and organic silver salts such as silver protein (mild and strong), silver lactate, silver citrate, or silver sulfadiazine. It is to be understood that this is not an exhaustive list of the silver compounds which may be used with the medical composition of the present invention and that other silver compounds may suitably be used. Furthermore, mixtures of silver compounds, or a silver compound and elemental silver, may also be suitable. Silver metal, such as silver foil or colloidal silver, may also be suitable in some embodiments.
  • the medical composition of the present invention may be included as a component of a topical composition of the type described in U.S. Pat. No. 5,980,918.
  • a topical composition is preferably applied directly to a wound or to a surgical site so that the immunostimulating and antimicrobial properties of the topical composition may work in conjunction to stimulate healing.
  • a topical composition which comprises the medical composition of the present invention may be formulated in various ways including those topical composition variously known as unguents, creams, gels, emollients, lotions and oils, each with a generally characteristic solvent composition and having a form ranging from liquid to semi-solid.
  • a topical composition may be applied directly by rubbing the composition onto the desired treatment area, or may be applied indirectly such as by coating the composition onto an applicator, a wound dressing, or other means of application.
  • a topical composition of the invention may contain, for example, about 0.05% to about 15% by weight of a ⁇ -glucan component, and about 0.05% to about 70% by weight of a silver-containing component.
  • the topical composition contains about 0.05% to about 15% by weight of a ⁇ -glucan component, and about 0.05% to about 15% by weight of a silver-containing component.
  • a particularly suitable combination is about 0.05% to about 15% by weight of (1-3)(1-4) ⁇ -D-glucan component, and about 0.05% to about 15% by weight of silver nitrate.
  • a topical formulation may include one or more of an ointment base, a solvent, a suspending/viscosity-increasing agent, an emulsifying/solubilizing agent, a stiffening agent, an emollient, and a preservative.
  • an ointment base a solvent
  • a suspending/viscosity-increasing agent emulsifying/solubilizing agent
  • a stiffening agent emollient
  • emollient emollient
  • a suitable ointment base may include white petrolatum, cod liver oil, mineral oil, shark oil, paraffin, lanolin, cetyl alcohol, and/or cetyl ester wax, and the like.
  • the solvent may suitably be primarily or entirely water. Additional solvents which may be added at generally lower concentrations include natural oils such as cod liver oil, mineral oil, etc., and glycerol or propylene glycol. In some embodiments, the water content of a cream or gel formulation is at least about 50% by weight.
  • a suspending/viscosity-increasing agent such as carrageenan
  • a topical composition comprising a solvent.
  • Other possible suspending/viscosity-increasing agents include polyvinyl alcohol, xanthan gum, agarose, alginate, guar gum, a carbomer such as CARBOPOL 940 (Noveon, Inc., Cleveland, Ohio), and carboxymethylcellulose, as well as mixtures thereof.
  • a variation in the concentration of suspending agents is compensated by varying the solvent concentration.
  • a stiffening agent useful in forming a topical composition with the medical composition of the present invention may comprise cetyl alcohol, cetyl esters wax, or paraffin.
  • a suitable emulsifying/solubilizing agent may suitably include sodium lauryl sulfate or non-ionic emulsifiers such as glyceryl stearate, PEG 100 stearate and triethanolamine.
  • a suspending/viscosity increasing agent suitable for use with the medical composition may suitably include polyvinyl alcohol, agarose, alginate, xanthan gum, guar gum, sodium carboxymethylcelluloses, or carbomer.
  • a preservative such as methyl paraben, ethyl paraben, butyl paraben, propyl paraben, benzalkonium chloride, benzoic acid, benzoic alcohol, imidurea, or diazolidinyl urea may also suitably be used in a topical composition formulated according to the present invention.
  • An ointment according to the present invention may comprise about 50% to about 99.5% by weight of petrolatum or alternate ointment base.
  • a lotion or cream of the present invention may include, for example, a cereal-derived ⁇ -glucan compound, a solvent, an emulsifying/solubilizing agent, a suspending/viscosity-increasing agent, and a preservative.
  • a specific formulation of a topical composition comprising the medical composition of the present invention and taking the form of a lotion may include 0.05-15 w/w % oat-derived ⁇ -D-glucan and 0.05-15 w/w % silver nitrate (AgNO 3 ). Additional components may include: 20-90 w/w % water, 3-60 w/w % petrolatum, 2-30 w/w % glycerol stearate, and 2-20 w/w % PEG 100 stearate.
  • Another formulation of a topical composition for application to the skin and mucosa for treating burns and wounds and other skin loss injuries and conditions comprises 0.05-15 w/w % ⁇ -D-glucan and a silver-containing component as active ingredients in a cream base, gel base or oil base.
  • a topical composition comprising the medical composition takes the form of a cream and includes ⁇ -glucan, a solvent including water, an ointment base, an emulsifying/solubilizing agent, a suspending/viscosity increasing agent, and a preservative.
  • a solvent including water, an ointment base, an emulsifying/solubilizing agent, a suspending/viscosity increasing agent, and a preservative.
  • the solvent may include an emollient such as glycerol or propylene glycol.
  • the ointment base typically makes up 3-60 w/w % of the topical composition and may comprise petrolatum, cod liver oil, mineral oil, shark oil, paraffin, lanolin, cetyl alcohol, and/or cetyl ester wax.
  • a suitable gel formation including the medical composition of the present invention comprises a gel base generally including water, at least one suspending/viscosity increasing agent, and optionally a preservative mixed with the medical composition.
  • the suspending/viscosity increasing agent(s) is typically chosen from a group that includes polyvinyl alcohol, sodium carboxymethylcellulose, xanthan gum, agarose, alginate, guar gum, and carbomer.
  • the suspending/viscosity increasing agent(s) may include one or more of the aforementioned group.
  • Such a gel preferably has a water base including at least about 50 w/w % water. More specifically, such a gel may comprise about 50-98 w/w % water and about 0.5-15 w/w % suspending/viscosity increasing agent(s).
  • a specific formulation of a lotion comprising the medical composition of the present invention was made as follows: An aqueous solution of oat derived ⁇ -glucan was prepared by dissolving 2 grams of oat derived ⁇ -glucan in 165 grams of water at 95° C. A separate oil-phase solution was prepared by mixing 20 grams petrolatum with 10 grams of a (49% glycerol stearate/51% PEG 100 stearate) blend. This blend may be replaced by equal amounts of the respective constituents or by an equivalent compound. The oil phase solution was heated to 65° C.
  • the medical composition of the present invention may be used in fabricating wound dressings that provide both immunostimulating and antimicrobial properties.
  • the medical composition of the present invention may, for example, be added to a mesh wound dressing of the type disclosed in U.S. Pat. No. 5,676,967 to Williams, et al. incorporated by reference above.
  • the medical composition containing a ⁇ -glucan component and a silver-containing component would be used to impregnate a mesh material.
  • the wound dressing may also include a vapor-permeable layer which is occlusive to moisture and bacteria.
  • mesh material refers to a woven, non-woven, or film material suitable as a substrate to which the medical composition of the present invention may be applied.
  • a mesh material may be of synthetic, animal, human, plant, or mineral origin. Synthetic materials from which a suitable mesh may be fabricated include polyester, polypropylene, polytetrafluoroethylene, expanded polytetrafluoroethylene, polyurethane, polyethylene terephthalate, polyglycolic acid, polyglactin, and silicone. Other types of meshes may be used, including but not limited to gauzes and organic meshes, and polymeric films.
  • Suitable organic surgical meshes may be derived from human sources, animal sources, and cadaveric sources.
  • Homologous mesh materials may be derived from the tissues of a donor, from animal tissues, or from cadaveric tissues.
  • Autologous mesh materials are derived from a patient's own body, and may comprise dermographs, fascia tissues, and dura mater.
  • an optional polymeric film may be applied to the mesh material.
  • the polymeric film is suitably a vapor-permeable material.
  • the film has a moisture-vapor transmission rate (MVTR) in a range suitable for medical or wound-dressing applications.
  • MVTR moisture-vapor transmission rate
  • a MVTR of about 1500 g/m 2 /24 hours or greater is desirable, although a film having a lower MVTR may also be suitable in some embodiments.
  • wound dressing 10 comprises an impregnated mesh material.
  • the mesh material is preferably a multifilament woven mesh netting 12 formed of thin polyester fibers 20 , though other types of meshes may be used, including but not being limited to gauzes, synthetic meshes, and organic meshes (of both autologous and homologous sources).
  • the mesh netting material 12 has a structure with holes or openings 14 that permit a solution containing the medical composition of the present invention to impregnate the mesh netting material 12 .
  • the wound dressing 10 may also comprise a vapor-permeable layer 22 , which is occlusive to moisture and bacteria.
  • the vapor-permeable layer 22 may be made, for example, of a film of butylene/poly(alkylene ether) phthalate plus stabilizer, and joined to surface 18 of the mesh netting material 12 by a thermal process or other means, and acts to prevent moisture and bacteria from entering the wound while allowing vapor to pass through the dressing 10 from the wound site into the air.
  • the ⁇ -glucan component of the medical composition is applied to the mesh material of the wound dressing to produce a concentration equal to about 0.01-50% of the dressing's dry weight, in some embodiments.
  • the silver-containing component of the medical composition is applied to the mesh material of the wound dressing to produce a concentration equal to about 0.01-15% of the dressing's dry weight, in some embodiments.
  • Additional components of the wound dressing may include a coating of a collagenic protein.
  • the optional collagenic protein component of the wound dressing may include a mixture of Type I and Type III collagens that makes up 0.1-20% of the dry weight of the dressing, for example.
  • Collagen is commercially available in several forms. While other collagenic protein materials may be used, a readily available material comprising a mixture of Type I and Type III collagens is a lyophilized, soluble, collagen fiber-like powder extracted from bovine hides.
  • Type II and/or Type IV collagens may also be used, but their lower solubility, higher hydrophobicity makes their controllable application as a suspension to fibers more difficult, and their subsequent transport into the wound proceeds at a lower rate.
  • a wound dressing which incorporates the medical composition of the present invention may comprise a polyester mesh netting formed of a woven monofilament polyester having a thickness of about 0.01-0.05 inches. To this netting is applied a coating that includes a ⁇ -glucan compound and a silver compound that are mixed with a collagenic protein in a ratio of 1:100 to 100:1 on a dry weight basis.
  • a wound dressing which comprises the medical composition of the present invention was made as follows: An aqueous solution of oat-derived ⁇ -glucan and silver nitrate was prepared. The solution contained 1.0wt.-% ⁇ -glucan and 0.3 wt.-% silver nitrate. This aqueous solution was used to impregnate the mesh netting of the dressing. The aqueous solution in the mesh netting of the dressing was then dehydrated at 25° C. Following dehydration, the completed wound dressing with the impregnated mesh netting was packaged and sterilized. The weight percentages (w/w %) of the compounds of the resulting exemplary wound dressing were as follows: ⁇ -D-glucan (oat derived) 31.3% Silver nitrate 9.8% Mesh netting 58.9% Total 100.0%
  • the medical compositions of the present invention may also be used in producing a biocompatible mesh device for treating or repairing tissue at a surgical site.
  • Surgical meshes are porous, gauze-like sheet materials which may be woven or spun from a variety of organic and synthetic materials. Examples of biocompatible surgical meshes incorporating ⁇ -glucan are given in U.S. patent application Ser. No. 09/406,551 to Klein, incorporated by reference above.
  • the biocompatible mesh device of the present invention comprises the medical composition described above, and a mesh matrix.
  • the phrase “mesh matrix” is used herein to refer to a biocompatible woven or non-woven mesh material.
  • the material from which a surgical mesh is made must be biocompatible, chemically and physically inert, non-toxic and non-carcinogenic, is preferably mechanically strong, and easily fabricated and sterilized.
  • Most synthetic surgical meshes are woven from monofilament or multifilament fibers to form a mesh having pores of varying sizes and geometries.
  • Other synthetic surgical meshes are formed in a node-and-fibril arrangement in which the mesh includes larger sections, or nodes, which are interconnected by fibrils of the mesh material.
  • Synthetic materials from which a biocompatible mesh matrix may be fabricated include polyester, polypropylene, polytetrafluoroethylene, expanded polytetrafluoroethylene, polyurethane, polyethylene terephthalate, polyglycolic acid, polyglactin, and silicone.
  • Other types of meshes may be used, including but not limited to gauzes and organic meshes.
  • Suitable organic surgical meshes that may be combined with the medical composition of the present invention may be derived from human sources, animal sources, and cadaveric sources.
  • Homologous mesh materials may be derived from the tissues of a donor, from animal tissues, or from cadaveric tissues.
  • Autologous mesh materials are derived from a patient's own body, and may comprise dermographs, fascia tissues, and dura mater.
  • a surgical mesh 28 typically takes the form of porous, gauze-like sheet of material 30 , which may be made from various organic materials (of both autologous and homologous sources) or synthetic materials.
  • the surgical mesh will be an implantable device, and may be suitable for providing reinforcement to a damaged tissue.
  • the most common use of surgical meshes involves the reinforcement of herniations.
  • Surgical meshes are also used in gynecological procedures including abdominal sacrocolopopexy and as suburethral slings.
  • a surgical mesh become incorporated into the tissues surrounding a surgical site.
  • One example of such a surgical procedure is the reinforcement of a herniation.
  • a surgical mesh of appropriate size and shape is placed over the newly repaired hernia and secured in place using sutures, staples, surgical adhesives, or any other suitable connecting means.
  • sutures, staples, surgical adhesives, or any other suitable connecting means As the tissues surrounding the surgical site heal, granulation tissues growing at and around the surgical site begin to produce an extracellular matrix which, in a process called fibrosis, infiltrates and attaches to the material of the surgical mesh secured over the surgical site. Incorporation of the surgical mesh into the surgical site by the extracellular matrix strengthens the tissues at the surgical site and helps prevent re-injury.
  • the medical composition of the present invention will be used to impregnate a mesh matrix in the same manner as described above for the wound dressing of the present invention.
  • the medical composition may be constituted as a film that is applied as a discrete layer 32 to one or both sides of the surgical mesh 28 by a thermal process or by other means.
  • the present invention further provides methods for treating tissue damaged by wound or burn.
  • the method comprises the steps of cleaning a site of damaged tissue, and applying topically to the site an antimicrobial and immunostimulating composition comprising a combination of a ⁇ -glucan component and a silver-containing component.
  • the method may further include repeated applications of the composition intermittently until healing of the damaged tissue is complete.
  • the topical compositions described above are suitable for use in the method.
  • the method comprises the steps of cleaning a site of damaged tissue, and covering the site with a wound dressing comprising a mesh material and a composition comprising an antimicrobially effective and immunostimulating amount of a combination of a ⁇ -glucan component and a silver-containing component.
  • a wound dressing comprising a mesh material and a composition comprising an antimicrobially effective and immunostimulating amount of a combination of a ⁇ -glucan component and a silver-containing component.
  • the present invention also provides a method for treating or repairing tissue at a surgical site.
  • the method comprises the step of applying to the surgical site a biocompatible mesh device, the mesh device comprising a mesh matrix and a composition comprising an antimicrobially effective and immunostimulating amount of a combination of a ⁇ -glucan component and a silver-containing component.
  • the mesh devices described above are suitable for use in the method.
  • the method may be suitable for treating or repairing tissue at a herniation site, or for other procedures listed above. In one particular application, the method may be suitable where the mesh device is required to provide reinforcement to the tissue. In another application, the method may be suitable where the mesh device is intended to become incorporated into the tissues surrounding a surgical site.
  • a method for manufacturing a medical composition comprising the step of combining, in an appropriate solvent, a ⁇ -glucan component and a silver-containing component in appropriate portions to provide an antimicrobial and immunostimulating composition.
  • Conventional methods may be used for combining the components.
  • the method is suitable for providing the medical compositions described above.
  • the method is suitable to provide a composition for topical application.
  • the method further comprises the step of coating or impregnating a mesh material to provide a wound dressing.
  • the method further comprising the step of impregnating a mesh matrix to provide a biocompatible mesh device suitable for treating or repairing tissue at a surgical site.
  • a standard zone-of-inhibition study was performed on the lotion and wound dressing exemplars described above.
  • the zone-of-inhibition test involved placing a quantity of the prepared lotion or wound dressing in a petri dish, which had been cultured with a particular bacterium.
  • the bacteria used in this test included: B. subtilis, B. vulgatus, C. albicans, E. coli, P. aeruginosa , and S. aureus .
  • the diameter of the prepared lotion or wound dressing placed in the cultured petri dishes was measured and recorded at the outset of the test. On the first, second, and fifth days thereafter the diameter of the zone of inhibition was measured and recorded.
  • Zone of inhibition in this test was defined as the area surrounding the prepared lotion or wound dressing on the petri dish which was uninhabited by the bacteria of the specific culture.
  • Table 1 reports data for the prepared lotion zone-of-inhibition test and Table 2 reports data for the prepared wound dressing zone-of-inhibition test.
  • albicans 1) 2.35 * 3.70 3.70 2) 2.23 * 3.55 3.65 Mean 2.29 * 3.63 3.68 E. coli 1) 2.05 2.78 2.78 2.68 2) 2.18 2.75 2.70 2.65 Mean 2.12 2.77 2.74 2.67 P. aeruginosa 2.13 3.08 3.03 3.03 1) 2) 2.15 3.00 3.00 3.00 Mean 2.14 3.04 3.02 3.02 S. aureus 1) 2.10 3.08 3.08 3.05 2) 2.25 3.05 3.05 3.03 Mean 2.18 3.07 3.07 3.04
  • aeruginosa 2.20 3.33 3.35 3.28 1) 2) 2.23 3.25 3.32 3.33 Mean 2.22 3.29 3.34 3.31 S. aureus 1) 2.15 3.30 3.30 3.30 2) 2.10 3.25 3.25 3.20 Mean 2.13 3.28 3.28 3.25
  • zone-of-inhibition tests are indicative of a strong antimicrobial effect for both the prepared lotion and the prepared wound dressing. Similar results are observed for a zone-of-inhibition test when a yeast-derived ⁇ -glucan is used in a medical composition as described herein.
  • ⁇ -glucan does not provide antimicrobial activity.
  • the results of the zone-of-inhibition tests described above indicate that ⁇ -glucan does not interfere with the antimicrobial activity that can be provided by a silver-containing component, even though ⁇ -glucan will promote growth of bacteria. Therefore, the combination of a silver-containing component and a ⁇ -glucan component can provide antimicrobial and immunostimulating properties to a medical composition.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Materials Engineering (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
US10/460,760 2000-03-30 2003-06-12 Antimicrobial and immunostimulating composition Abandoned US20040005364A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/460,760 US20040005364A1 (en) 2000-03-30 2003-06-12 Antimicrobial and immunostimulating composition
US11/428,929 US20060240083A1 (en) 2000-03-30 2006-07-06 Antimicrobial and immunostimulating composition
US13/156,566 US8231894B2 (en) 2000-03-30 2011-06-09 Antimicrobial and immunostimulating composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53865500A 2000-03-30 2000-03-30
US10/460,760 US20040005364A1 (en) 2000-03-30 2003-06-12 Antimicrobial and immunostimulating composition

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US53865500A Continuation 2000-03-30 2000-03-30
US53865500A Continuation-In-Part 2000-03-30 2000-03-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/428,929 Division US20060240083A1 (en) 2000-03-30 2006-07-06 Antimicrobial and immunostimulating composition

Publications (1)

Publication Number Publication Date
US20040005364A1 true US20040005364A1 (en) 2004-01-08

Family

ID=24147847

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/460,760 Abandoned US20040005364A1 (en) 2000-03-30 2003-06-12 Antimicrobial and immunostimulating composition
US11/428,929 Abandoned US20060240083A1 (en) 2000-03-30 2006-07-06 Antimicrobial and immunostimulating composition
US13/156,566 Expired - Fee Related US8231894B2 (en) 2000-03-30 2011-06-09 Antimicrobial and immunostimulating composition

Family Applications After (2)

Application Number Title Priority Date Filing Date
US11/428,929 Abandoned US20060240083A1 (en) 2000-03-30 2006-07-06 Antimicrobial and immunostimulating composition
US13/156,566 Expired - Fee Related US8231894B2 (en) 2000-03-30 2011-06-09 Antimicrobial and immunostimulating composition

Country Status (4)

Country Link
US (3) US20040005364A1 (fr)
EP (1) EP1267795A1 (fr)
AU (1) AU2001250875A1 (fr)
WO (1) WO2001074300A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050031674A1 (en) * 2001-12-11 2005-02-10 Ceapro, Inc Cereal beta glucan compositions, methods of preparation and uses thereof
US20060155041A1 (en) * 2002-08-30 2006-07-13 Yoshiaki Suzuki Biological repair material compatible with biological tissue adhesive
US10058542B1 (en) * 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
US10568983B2 (en) * 2014-10-24 2020-02-25 Sefar Ag Wound dressing material and method for its production
CN111097067A (zh) * 2020-01-10 2020-05-05 温州医科大学 一种促伤口快速愈合的抗菌性医用敷料及其制备方法
CN115736255A (zh) * 2022-11-09 2023-03-07 华南理工大学 一种高分子量燕麦β-葡聚糖提取物的应用

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7137968B1 (en) 2000-03-13 2006-11-21 Nucryst Pharmaceuticals Corp. Transcutaneous medical device dressings and method of use
US7427416B2 (en) 2000-07-27 2008-09-23 Nucryst Pharmaceuticals Corp. Methods of treating conditions using metal-containing materials
US20030180379A1 (en) 2000-07-27 2003-09-25 Burrell Robert E. Solutions and aerosols of metal-containing compounds
US7008647B2 (en) 2001-04-23 2006-03-07 Nucryst Pharmaceuticals Corp. Treatment of acne
US7255881B2 (en) 2000-07-27 2007-08-14 Nucryst Pharmaceuticals Corp. Metal-containing materials
US20030185901A1 (en) 2000-07-27 2003-10-02 Burrell Robert E. Methods of treating conditions with a metal-containing material
US6989157B2 (en) 2000-07-27 2006-01-24 Nucryst Pharmaceuticals Corp. Dry powders of metal-containing compounds
US7001617B2 (en) 2001-04-23 2006-02-21 Nueryst Pharmaceuticals Corp. Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals
AU2001212050A1 (en) * 2000-10-13 2002-04-29 Brennen Medical, Inc. Coated surgical mesh
EP1383521A2 (fr) 2001-04-23 2004-01-28 Nucryst Pharmaceuticals Corp. Procede pour induire une apoptose et pour inhiber des metalloproteinases matricielles par utilisation de metaux antimicrobiens
GB0124530D0 (en) * 2001-10-12 2001-12-05 Acordis Speciality Fibres Ltd Improved fabric
US7201925B2 (en) 2002-04-23 2007-04-10 Nueryst Pharmaceuticals Corp. Treatment of ungual and subungual diseases
US8100872B2 (en) 2002-10-23 2012-01-24 Tyco Healthcare Group Lp Medical dressing containing antimicrobial agent
JP4922560B2 (ja) 2002-12-23 2012-04-25 ウイリアム、マーシュ、ライス、ユーニヴァーサティ 線維細胞への分化の検出方法、線維症を抑制する組成物および方法
WO2004096862A2 (fr) * 2003-05-02 2004-11-11 Ceapro Inc. Procede ameliore d'extraction et de purification de glucane-$g(b) de cereales
EP1778169A1 (fr) * 2004-08-13 2007-05-02 Symrise GmbH & Co. KG Beta-(1,3)-beta-(1,4)-glucan en tant que vehicule pour des substances chimiques
US20100203088A1 (en) * 2005-06-08 2010-08-12 Khandelwal Sanjeev Silver Nanoparticle Dispersion Formulation
GB0603487D0 (en) * 2006-02-22 2006-04-05 Agt Sciences Ltd Delivery means
CA2708004C (fr) 2006-12-04 2015-12-01 Promedior, Inc. Therapie conjointe pour le traitement de maladies fibrotiques
US20080171068A1 (en) * 2007-01-17 2008-07-17 Etcetera Llc Antimicrobial, infection-control and odor-control film and film composite
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
US8497243B2 (en) 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
US8865227B2 (en) 2007-12-20 2014-10-21 Smith & Nephew (Overseas) Limited Metal carbonate particles and methods of making thereof
CN101407586B (zh) * 2008-07-15 2011-04-27 中山大学 一种纳米银/葡聚糖凝胶杂化材料及其制备方法和应用
WO2010104961A1 (fr) 2009-03-11 2010-09-16 Promedior, Inc. Méthodes de traitement de troubles auto-immuns
PT2405928T (pt) 2009-03-11 2017-02-07 Promedior Inc Métodos de tratamento e de diagnóstico para patologias de hipersensibilidade
UA110323C2 (en) 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
EP2443144B1 (fr) 2009-06-17 2015-08-19 Promedior, Inc. Variants de la sap et leur utilisation
GB201105829D0 (en) * 2011-04-06 2011-05-18 Convatec Technologies Inc Antimicrobial compositions
US20130150764A1 (en) * 2011-12-09 2013-06-13 Tyco Healthcare Group Lp Non-Adherent Wound Dressings and Related Methods Therefor
US9402770B2 (en) 2011-12-09 2016-08-02 Covidien Antimicrobial non-adherent dressings and related methods therefor
CN104918589B (zh) * 2013-01-21 2019-11-01 Kpr美国有限责任公司 抗微生物非粘附性敷料及相关使用方法
EP2896396A1 (fr) * 2014-01-20 2015-07-22 Abem Kimya Tibbi Malzemeler Yönetim Danismanligi Temizlik Servis Hizmetleri Sanayi Ve Dis Ticaret Limited Sirketi Formulation à base de plantes médicinales topiques pour le traitement des plaies topiques
CN105559069A (zh) * 2016-01-09 2016-05-11 深圳爱易瑞科技有限公司 一种胶原蛋白的组合物及其制备方法
WO2018212351A1 (fr) 2017-05-19 2018-11-22 Daikin America, Inc. Composition et procédé de production de la composition
KR102321066B1 (ko) * 2018-06-22 2021-11-03 (주)큐젠바이오텍 베타글루칸, 글리시틴 및 4',6,7-트리메톡시이소플라본을 포함하는 창상 치료 또는 피부 활성용 약학적 조성물
US20220354987A1 (en) * 2019-06-28 2022-11-10 Systagenix Wound Management, Limited Collagen polysaccharide wound dressing
US11701451B1 (en) 2022-03-11 2023-07-18 Carbon Medical Technologies, Inc. Soft tissue filler and methods

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358516B1 (en) * 1998-08-21 2002-03-19 Norris R. Harod One-step system for cleansing, conditioning, and treating the skin

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837024A (en) * 1984-02-24 1989-06-06 The Regents Of The University Of California Compositions, articles and mehtod for improving wound healing
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
GB8607159D0 (en) * 1986-03-22 1986-04-30 Smith & Nephew Ass Pharmaceutical composition
US4728323A (en) * 1986-07-24 1988-03-01 Minnesota Mining And Manufacturing Company Antimicrobial wound dressings
US4902553A (en) * 1987-12-04 1990-02-20 Minnesota Mining And Manufacturing Company Disposable products
US5223491A (en) * 1989-11-09 1993-06-29 Donzis Byron A Method for revitalizing skin by applying topically water insoluble glucan
US5658957A (en) * 1991-03-01 1997-08-19 Warner Lambert Company Immunostimulating wound healing compositions and method for preparing and using same
DE69229548T2 (de) * 1991-04-10 2000-02-17 Christopher C. Capelli Antimikrobielle zusammensetzungen für medizinische anwendungen
DE4113158A1 (de) * 1991-04-23 1992-10-29 Bayer Ag Mikrobizide wirkstoffkombinationen
US5158772A (en) * 1991-09-23 1992-10-27 Davis Walter B Unique bacterial polysaccharide polymer gel in cosmetics, pharmaceuticals and foods
US5635184A (en) * 1993-06-10 1997-06-03 Eduardo Haim Pinto Essential oil composition with bactericide activity
US5482714A (en) * 1994-07-08 1996-01-09 Healthpoint Medical Limited Partnership Water impermeable skin protectant based upon reverse water emulsion
US5762917A (en) * 1994-09-27 1998-06-09 Virotex Corporation Method and composition for cleansing wounds with minimal cytotoxicity for minimal scarring
US5676967A (en) * 1995-04-18 1997-10-14 Brennen Medical, Inc. Mesh matrix wound dressing
WO1997045533A1 (fr) * 1996-05-28 1997-12-04 The Regents Of The University Of Michigan Reconstitution de tissus buccaux
WO1999001166A1 (fr) * 1997-07-02 1999-01-14 Coloplast A/S Procede de preparation d'un materiau poreux non fibreux
US5980918A (en) * 1997-10-24 1999-11-09 Brennen Medical, Inc. β-D-glucan topical composition
US6153212A (en) * 1998-10-02 2000-11-28 Guilford Pharmaceuticals Inc. Biodegradable terephthalate polyester-poly (phosphonate) compositions, articles, and methods of using the same
US20040060620A1 (en) * 2000-10-05 2004-04-01 Johns Hopkins University High performance nanostructured materials and methods of making the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358516B1 (en) * 1998-08-21 2002-03-19 Norris R. Harod One-step system for cleansing, conditioning, and treating the skin

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050031674A1 (en) * 2001-12-11 2005-02-10 Ceapro, Inc Cereal beta glucan compositions, methods of preparation and uses thereof
US20100158988A1 (en) * 2001-12-11 2010-06-24 Ceapro, Inc. Cereal beta glucan compositions, methods of preparation and uses thereof
US8632798B2 (en) 2001-12-11 2014-01-21 Ceapro Inc. Cereal β glucan compositions, methods of preparation and uses thereof
US20060155041A1 (en) * 2002-08-30 2006-07-13 Yoshiaki Suzuki Biological repair material compatible with biological tissue adhesive
US7722934B2 (en) * 2002-08-30 2010-05-25 Riken Biological repair material compatible with biological tissue adhesive
US10058542B1 (en) * 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
US11013730B1 (en) 2014-09-12 2021-05-25 Thioredoxin Systems Ab Composition comprising selenazol or thiazalone derivatives and silver and method of treatment therewith
US10568983B2 (en) * 2014-10-24 2020-02-25 Sefar Ag Wound dressing material and method for its production
CN111097067A (zh) * 2020-01-10 2020-05-05 温州医科大学 一种促伤口快速愈合的抗菌性医用敷料及其制备方法
CN115736255A (zh) * 2022-11-09 2023-03-07 华南理工大学 一种高分子量燕麦β-葡聚糖提取物的应用

Also Published As

Publication number Publication date
EP1267795A1 (fr) 2003-01-02
US20060240083A1 (en) 2006-10-26
AU2001250875A1 (en) 2001-10-15
US8231894B2 (en) 2012-07-31
US20110244021A1 (en) 2011-10-06
WO2001074300A1 (fr) 2001-10-11

Similar Documents

Publication Publication Date Title
US8231894B2 (en) Antimicrobial and immunostimulating composition
US6706279B1 (en) Wound dressing
EP1216065B1 (fr) Compositions contenant de l'argent, dispositifs et procedes de preparation
EP1377245B1 (fr) Revetement immunostimulant destine a des dispositifs chirurgicaux
US6897349B2 (en) Silver-containing compositions, devices and methods for making
DE69817574T2 (de) Herstellungsmethode für ein faserfreies, poröses material
EP2203175B1 (fr) Préparation à base de chitosan-glucan permettant de soigner des blessures et d'enpêcher un pansement d'adhérer à la plaie
US20050214376A1 (en) Hydrogel-containing medical articles and methods of using and making the same
DE102006001954B4 (de) Antiseptische Alginatzubereitung, Verfahren zu deren Herstellung, sowie deren Verwendung
EP2341866A1 (fr) Filet chirurgical enrobe
DE69018684T2 (de) Antimikrobielle Kunststoffmaterialien mit Breitbandwirkung.
WO2007121912A2 (fr) Pansement multicouche
EP1593399A2 (fr) Pansement pour plaie biorésorbable à base de collagène
EP1922089B1 (fr) Biomateriaux a base de carboxymethylcellulose salifiee au zinc associe a des derives d'acide hyaluronique
DE69029969T2 (de) Kunsthaut
RU2437681C1 (ru) Раневое покрытие с лечебным действием
CN106110369A (zh) 一种医用复合型透明质酸敷料及其制备方法
DE60223371T2 (de) Konjugate von polymeren natürlichen ursprungs
TWI519302B (zh) 創傷癒合組合物及其用途
EP1005844B1 (fr) Tissu pour bandages ayant une action therapeutique prolongee
CN115286737B (zh) 一种促愈凝胶前体、其制备和基于它的创面凝胶及其制备
BR102023014665A2 (pt) Curativos a base de quitosana com nanopartículas de prata para úlceras por pressão
US20230263933A1 (en) Wound hydrogel for managing acute and chronic wounds in human and animals
DE102020117622A1 (de) Wundreinigungstuch
MXPA00003316A (en) &bgr;-D GLUCAN TOPICAL COMPOSITION

Legal Events

Date Code Title Description
AS Assignment

Owner name: BRENNAN MEDICAL, INC., MINNESOTA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KLEIN, BARBARA K.;KATZNER, LEO D.;REEL/FRAME:014413/0181

Effective date: 20030714

AS Assignment

Owner name: BRENNEN MEDICAL, LLC, MINNESOTA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BRENNEN MEDICAL, INC.;REEL/FRAME:017370/0962

Effective date: 20060322

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: BRENNEN MEDICAL, INC., MINNESOTA

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF THE RECEIVING PARTY FROM BRENNAN MEDICAL, INC. TO BRENNEN MEDICAL, INC. PREVIOUSLY RECORDED ON REEL 014413 FRAME 0181;ASSIGNORS:KLEIN, BARBARA K.;KATZNER, LEO D.;REEL/FRAME:018739/0272

Effective date: 20070110